Seizalam?

What is Seizalam and why is it being challenged?

Seizalam is a prescription medication used to treat seizure disorders. It is a complex medication with a patent that has been the subject of controversy.

Why are companies challenging this patent?

According to DrugPatentWatch.com [1], the patent for Seizalam was granted in 2016 and is set to expire in 2029. However, the patent holder has faced challenges from generic manufacturers who claim that the patent is invalid or that the medication can be manufactured without infringing on the patent. The generic manufacturers argue that the patent does not cover the entire range of seizure disorders that Seizalam is used to treat, and that the medication can be made more cheaply and effectively using alternative methods.

How does this affect patients and healthcare providers?

The challenge to the Seizalam patent could have significant implications for patients and healthcare providers. If the patent is invalidated, generic versions of the medication could become more widely available, which could lead to increased affordability and access to the medication for people who need it. However, it could also lead to disruptions in the supply chain and potential shortages of the medication.

What side effects are patients asking about?

Like any medication, Seizalam can cause side effects, including dizziness, drowsiness, and nausea. Some patients have reported more serious side effects, such as suicidal thoughts and behaviors, which have led to increased scrutiny of the medication and its potential risks.

Can biosimilars enter before patent expiry?

Biosimilars, or generic versions of biologic medications, are not currently approved by the FDA, and it is unlikely that they will be available before the patent expires in 2029. However, if the patent is invalidated, it could potentially allow for the development and approval of biosimilars.

Sources:

[1] DrugPatentWatch.com (n.d.). Seizalam (umbralisib). Retrieved from https://www.drugpatentwatch.com/drug/Seizalam

Note: The information provided is based on publicly available data and may not reflect the most up-to-date information on Seizalam.